PSMA PET scans to predict outcomes in newly diagnosed prostate cancer
Studies how well PSMA PET scans predict outcomes in newly diagnosed prostate cancer.
Plain-language title generated from the registry record
Registry title: A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Key facts
- Where
- Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, and Yinchuan, ChinaSee the 9 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07474142, who can take part
Where in China
- The First Hospital of Lanzhou UniversityLanzhou, ChinaTaking people
- Weinan Central HospitalWeinan, ChinaTaking people
- Shaanxi provincial people's hospitalXi'an, ChinaTaking people
- Xijing 986 HospitalXi'an, ChinaTaking people
- Xijing Hospital, Fourth Military Medical UniversityXi'an, ChinaTaking people
- The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, ChinaTaking people
- Qinghai university affiliated hospitalXining, ChinaTaking people
- Affiliated Hospital of Yan'an UniversityYan’an, ChinaTaking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT07474142
- Record updated
- 16 March 2026
- Original description
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the mixture of different disease stages may compromise the accuracy of prognostic tools. This study aims to specifically investigate the prognostic value of initial staging PSMA PET for progression-free survival in patients with newly diagnosed, treatment-naïve prostate cancer, and to develop corresponding prognostic tools.Read full original descriptionShow less
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the mixture of different disease stages may compromise the accuracy of prognostic tools. This study aims to specifically investigate the prognostic value of initial staging PSMA PET for progression-free survival in patients with newly diagnosed, treatment-naïve prostate cancer, and to develop corresponding prognostic tools.
Need:
The prognostic value of initial staging with PSMA PET is needed for treatment management and study design.
Primary Outcome:
To assess the prognostic value of initial staging by PSMA PET: generate a prognostic tool (PSMA-VISION score) based on initial staging of PSMA PET to predict progression-free survival.
Secondary Outcomes:
To compare PSMA-VISION score with the other prognostic tools (such as NCCN, STARCAP, PPP nomogram, PPP2 nomogram, etc.) and to evaluate the prognostic value of initial staging by PSMA PET to predict overall survival (OS). The correlation with clinicopathological variables and prediction of early progression (Exploratory) was also investigated.
Inclusion:
1. Patients with pathologically confirmed prostate cancer by prostate biopsy. 2. Undergone PSMA PET examination as initial staging before any treatment. 3. Have at least 2 years of follow-up data for progression-free survival and overall survival.
Exclusion Criteria:
1. Patients undergone any prior prostate cancer treatment before undergoing PSMA PET imaging. 2. Patients with metastasized or disseminated malignancy other than prostate cancer 3. Patients with neuroendocrine prostate cancer.
Inclusion: Patients with pathologically confirmed prostate cancer by prostate biopsy; Undergone PSMA PET examination as initial staging before any treatment; Have at least 2 years of follow-up data for progression-free survival and overall survival.
Exclusion: Patients undergone any prior prostate cancer treatment before undergoing PSMA PET imaging; Patients with metastasized or disseminated malignancy other than prostate cancer; Patients with neuroendocrine prostate cancer.